Zerion and Aché Partner to Advance Oncology and Neuroscience Formulations

Zerion Pharma A/S creates its own unique drug formulations and provides its Dispersome technology platform, announcing a collaboration with Aché Laboratórios Farmacêuticos S.A. (Aché), a leading pharmaceutical company in Brazil. The collaboration intends to leverage Zerion’s know-how and its Dispersome technology to enhance the formulation of two pharmaceutical products in oncology and neuroscience that are presently sold globally, each generating revenue in the billion-dollar range.

Through the partnership, Zerion’s Dispersome technology will be utilized to create more patient-friendly formulations of the drug products, focusing on enhancing their solubility, bioavailability, and drug loading capacity. Consequently, the patients will gain from lessening their daily medication load. One drug product has been developed to the prototype phase by Zerion and tested in animal studies.

“We are very pleased to have entered this partnership with Aché, which we consider a true first mover and one of the most innovative and patient-focused companies in Latin America. I am grateful for Aché’s confidence in our technology and competencies and convinced that our collaboration will be successful in bringing better drug products to the market not only in Latin America but on a global scale”, says Ole Wiborg, CEO of Zerion Pharma.